# Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA-IRVINE · 2021 · $71,810

## Abstract

The supplement instructions PA‐21-071 state: “At minimum, the Research Strategy section
should be completed and must include a summary or abstract of the funded parent award or
project. Other sections should also be included if they are being changed by the proposed
supplement activities.”
The original Project Summary document has not changed as a result of the proposed
supplement activities.

## Key facts

- **NIH application ID:** 10406778
- **Project number:** 3R01NS109423-02S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Daniela Annenelie Bota
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $71,810
- **Award type:** 3
- **Project period:** 2020-09-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10406778

## Citation

> US National Institutes of Health, RePORTER application 10406778, Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma (3R01NS109423-02S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10406778. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*